A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors

por Papadopoulos, Kyriakos P, Tsai, Frank, Hamid, Omid, Xiao, Feng, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Karakunnel, Joyson J, Lai, Dominic W, Mahipal, Amit
Publicado 2015

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic...

por Kelly, Ronan J, Chung, Ki, Gu, Yu, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Tavakkoli, Fatemeh, Karakunnel, Joyson J, Lai, Dominic W, Almhanna, Khaldoun
Publicado 2015

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

por Rebelatto, Marlon C., Midha, Anita, Mistry, Amita, Sabalos, Constantine, Schechter, Nicole, Li, Xia, Jin, Xiaoping, Steele, Keith E., Robbins, Paul B., Blake-Haskins, John A., Walker, Jill
Publicado 2016

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

por Arbour, Kathryn C., Naidoo, Jarushka, Steele, Keith E., Ni, Ai, Moreira, Andre L., Rekhtman, Natasha, Robbins, Paul B., Karakunnel, Joyson, Rimner, Andreas, Huang, James, Riely, Gregory J., Hellmann, Matthew D.
Publicado 2017

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

por Dobbin, Kevin K., Cesano, Alessandra, Alvarez, John, Hawtin, Rachael, Janetzki, Sylvia, Kirsch, Ilan, Masucci, Giuseppe V., Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Zhang, Jenny, Butterfield, Lisa H., Thurin, Magdalena
Publicado 2016

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

por Masucci, Giuseppe V., Cesano, Alessandra, Hawtin, Rachael, Janetzki, Sylvia, Zhang, Jenny, Kirsch, Ilan, Dobbin, Kevin K., Alvarez, John, Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Butterfield, Lisa H., Thurin, Magdalena
Publicado 2016

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase...

por Bilen, Mehmet A., Rini, Brian I., Voss, Martin H., Larkin, James, Haanen, John B.A.G., Albiges, Laurence, Pagliaro, Lance C., Voog, Eric G., Lam, Elaine T., Kislov, Nikolay, McGregor, Bradley A., Lalani, Aly-Khan A., Huang, Bo, di Pietro, Alessandra, Krulewicz, Stan, Robbins, Paul B., Choueiri, Toni K.
Publicado 2022

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

por Karasarides, Maria, Cogdill, Alexandria P., Robbins, Paul B., Bowden, Michaela, Burton, Elizabeth M., Butterfield, Lisa H., Cesano, Alessandra, Hammer, Christian, Haymaker, Cara L., Horak, Christine E., McGee, Heather M., Monette, Anne, Rudqvist, Nils-Petter, Spencer, Christine N., Sweis, Randy F., Vincent, Benjamin G., Wennerberg, Erik, Yuan, Jianda, Zappasodi, Roberta, Lucey, Vanessa M. Hubbard, Wells, Daniel K., LaVallee, Theresa
Publicado 2022